Health Populi June 30, 2021
Jane Sarasohn-Kahn

The FDA’s approval of the first therapy to treat Alzheimer’s Disease in over twenty years brought attention to a not-yet-convened debate of U.S. health care costs and spending, innovation, and return-on-the-investment (as well as “for whom” do the returns accrue).

In my latest post for Medecision, I explore different angles on the Aduhelm and Alzheimer’s discussion, covering:

  • The macro- and micro-economics of Alzheimer’s and the $56,000 list price for the drug
  • The FDA regulatory process and aftermath
  • U.S. consumers’ bipartisan support for drug price regulation through Medicare negotiation and private/commercial sector adoption
  • Congressional legislation addressing the price of medicines in the U.S., and
  • Future prospects for value-based pricing of medicines and health care.

I concluded the essay by...

Today's Sponsors

Transcarent
SalesSparx
Canton & Company

Today's Sponsors

Oscar
Curation Health

Today's Sponsor

TripleTree

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Insurance, Medicare, Patient / Consumer, Pharma / Biotech, Pricing / Spending, Provider
A Proven Path To Re-Energizing Medicare Innovation
A Clear Path to Standardized, Medicare Cost Report Reimbursements and Cloud-based Technologies
Medicare Coverage of Innovative Technology Program for FDA Breakthrough Devices: from Delayed to Repealed
AHA recommends focal points for next decade of Medicare and Medicaid innovation
Innovation At The Centers For Medicare And Medicaid Services: A Vision For The Next 10 Years